Scarica l'app Stockscreener
8.32
4.70%
-0.41
Dopo l'orario di chiusura:
8.68
0.36
+4.33%
Precedente Chiudi:
$8.73
Aprire:
$8.69
Volume 24 ore:
186.43K
Relative Volume:
0.79
Capitalizzazione di mercato:
$114.48M
Reddito:
-
Utile/perdita netta:
$-56.20M
Rapporto P/E:
-2.3305
EPS:
-3.57
Flusso di cassa netto:
$-39.97M
1 W Prestazione:
-14.67%
1M Prestazione:
-1.07%
6M Prestazione:
+60.62%
1 anno Prestazione:
+30.61%
Intervallo 1D:
$8.22
$8.8121
Intervallo di 1 settimana:
$8.22
$9.78
Portata 52W:
$4.53
$22.49
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewswire
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE:ANVS) Raised to Buy at Maxim Group - MarketBeat
Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference - MSN
Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies - Barchart
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - The Manila Times
Annovis Bio files three drug patents - Pennsylvania Business Report
Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio To Continue Alzheimer's Disease Clinical Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Yahoo Finance
Annovis Bio shares hold Buy rating from HC Wainwright - Investing.com India
Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish - Barchart
Annovis Bio shares hold Buy rating from HC Wainwright By Investing.com - Investing.com UK
In the Green: Annovis Bio Inc (ANVS) Closes at 7.98, Up/Down 6.26 from Previous Day - The Dwinnex
Annovis Bio (NYSE:ANVS) Given Buy Rating at HC Wainwright - MarketBeat
(ANVS) Investment Analysis and Advice - Stock Traders Daily
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials - MyChesCo
Annovis Bio (ANVS) Stock Soars After FDA Approval - Stocks Telegraph
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - The Manila Times
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - GlobeNewswire
Freedom Village Hosts Successful Third Annual Walk to End Alzheimer’s - MyChesCo
(ANVS) On The My Stocks Page - Stock Traders Daily
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
ANVSAnnovis Bio, Inc. Latest Stock News & Market Updates - StockTitan
Brookline Capital Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation - MSN
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - ForexTV.com
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for ... - The Bakersfield Californian
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Rating of "Buy" from Analysts - MarketBeat
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD - MSN
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations - The Manila Times
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential - GlobeNewswire
19,907 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by XTX Topco Ltd - Defense World
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment - MSN
Annovis Bio stock outlook supported by innovative neurodegenerative therapies - Investing.com India
Annovis Bio: Against The Grain In Alzheimer's Disease - Life Science Leader Magazine
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition - cnhinews.com
Annovis Bio (NYSE:ANVS) Rating Reiterated by HC Wainwright - MarketBeat
Annovis Bio files three new patents for combination therapies - TipRanks
Annovis Bio files patents for neurodegenerative treatment combos - Investing.com
Annovis Bio Files Patents for Neurodegenerative Combination Therapies - TipRanks
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - GlobeNewswire
Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom - Seeking Alpha
Anavex Lf SC (AVXL-Q) QuotePress Release - The Globe and Mail
Longeveron Inc (LGVN-Q) QuotePress Release - The Globe and Mail
(ANVS) Long Term Investment Analysis - Stock Traders Daily
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):